Triazole derivatives with improved in vitro antifungal activity over azole drugs

References

• Singh N Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices Clin Infect Dis 2001 33 10 1692 1696 11641825
   PubMed Web of Science ®Google Scholar
• Ablordeppey SY Fan P Ablordeppey JH Mardenborough L Systemic antifungal agents against AIDS-related opportunistic infections: current status and emerging drugs in development Curr Med Chem 1999 6 12 1151 1195 10519919
   PubMed Web of Science ®Google Scholar
• Wildfeuer A Seidl HP Paule I Haberreiter A In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin Mycoses 1998 41 7–8 309 319 9861837
   PubMed Web of Science ®Google Scholar
• Georgopapadakou NH Antifungals: mechanism of action and resistance, established and novel drugs Curr Opin Microbiol 1998 1 5 547 557 10066533
   PubMed Web of Science ®Google Scholar
• Georgopapadakou NH Walsh TJ Antifungal agents: chemotherapeutic targets and immunologic strategies Antimicrob Agents Chemother 1996 40 2 279 291 8834867
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP Mantadakis E Samonis G Systemic mycoses in the immunocompromised host: an update in antifungal therapy J Hosp Infect 2003 53 4 243 258 12660121
   PubMed Web of Science ®Google Scholar
• White TC Marr KA Bowden RA Clinical, cellular, and molecular factors that contribute to antifungal drug resistance Clin Microbiol Rev 1998 11 2 382 402 9564569
   PubMed Web of Science ®Google Scholar
• Wong-Beringer A Kriengkauykiat J Systemic antifungal therapy: new options, new challenges Pharmacotherapy 2003 23 11 1441 1462 14620391
   PubMed Web of Science ®Google Scholar
• Ghannoum MA Rice LB Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance Clin Microbiol Rev 1999 12 4 501 517 10515900
   PubMed Web of Science ®Google Scholar
• Sheehan DJ Hitchcock CA Sibley CM Current and emerging azole antifungal agents Clin Microbiol Rev 1999 12 1 40 79 9880474
   PubMed Web of Science ®Google Scholar
• Sheng CQ Zhang WN Ji HT Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking J Med Chem 2006 49 8 2512 2525 16610794
   PubMed Web of Science ®Google Scholar
• Pfaller MA Messer SA Hollis RJ Jones RN In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans Antimicrob Agents Chemother 2001 45 10 2862 2864 11557481
   PubMed Web of Science ®Google Scholar
• Lepesheva GI Hargrove TY Ott RD Nes WD Waterman MR Biodiversity of CYP51 in trypanosomes Biochem Soc Trans 2006 34 Pt 6 1161 1164 17073776
   PubMed Web of Science ®Google Scholar
• Lewis RE Current concepts in antifungal pharmacology Mayo Clin Proc 2011 86 8 805 817 21803962
   PubMed Web of Science ®Google Scholar
• Di Santo R Tafi A Costi R Antifungal agents. 11. N-substituted derivatives of 1-[(aryl)(4-aryl-1 H-pyrrol-3-yl) methyl]-1 H-imidazole: synthesis, anti-candida activity, and QSAR studies J Med Chem 2005 48 16 5140 5153 16078834
   PubMed Web of Science ®Google Scholar
• Odds FC Brown AJ Gow NA Antifungal agents: mechanisms of action Trends Microbiol 2003 11 6 272 279 12823944
   PubMed Web of Science ®Google Scholar
• Shyadehi AZ Lamb DC Kelly SL The mechanism of the acyl-carbon bond cleavage reaction catalyzed by recombinant sterol 14 alpha-demethylase of Candida albicans (other names are: lanosterol 14 alpha-demethylase, P-45014DM, and CYP51) J Biol Chem 1996 271 21 12445 12450 8647850
   PubMed Web of Science ®Google Scholar
• Chai X Zhang J Hu H Design, synthesis, and biological evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14 alpha-demethylase Eur J Med Chem 2009 44 5 1913 1920 19097674
   PubMed Web of Science ®Google Scholar
• Chai X Zhang J Yu S Design, synthesis, and biological evaluation of novel 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted benzylamino-2-propanols Bioorg Med Chem Lett 2009 19 6 1811 1814 19231179
   PubMed Web of Science ®Google Scholar
• Chai X Zhang J Cao Y New azoles with antifungal activity: Design, synthesis, and molecular docking Bioorg Med Chem Lett 2011 21 2 686 689 21190856
   PubMed Web of Science ®Google Scholar
• Chai X Zhang J Cao Y Design, synthesis and molecular docking studies of novel triazole as antifungal agent Eur J Med Chem 2011 46 7 3167 3176 21531485
   PubMed Web of Science ®Google Scholar
• Jiang Y Cao Y Zhang J Design, synthesis and antifungal evaluation of 1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl) propyl)-1H- 1,2,4-triazol-5(4H)-one Eur J Med Chem 2011 46 7 3135 3141 21354675
   PubMed Web of Science ®Google Scholar
• Xu J Cao Y Zhang J Design, synthesis and antifungal activities of novel 1,2,4-triazole derivatives Eur J Med Chem 2011 46 7 3142 3148 21420761
   PubMed Web of Science ®Google Scholar
• Aoyama Y Yoshida Y Nishino T Isolation and characterization of an altered cytochrome P-450 from a yeast mutant defective in lanosterol 14 alpha-demethylation J Biol Chem 1987 262 29 14260 14264 3115990
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute (CLSI) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts Approved standard Document M38-A3 Wayne, PA 2002
   Google Scholar
• Ji HT Zhang WN Zhang M Structure-based de novo design, synthesis, and biological evaluation of non-azole inhibitors specific for lanosterol 14 alpha-demethylase of fungi J Med Chem 2003 46 4 474 485 12570370
   PubMed Web of Science ®Google Scholar
• Ji H Zhang W Zhou Y A three-dimensional model of lanosterol 14α-demethylase of Candida albicans and its interaction with azole antifungals J Med Chem 2000 43 13 2493 2505 10891108
   PubMed Web of Science ®Google Scholar